Trimetrexate

Trimetrexate (CI-898) is an antibiotic, also a potent and orally active dihydrofolate reductase (DHFR) inhibitor, reducing the production of DNA and RNA precursors and leading to cell death, with IC50 values of 4.74 nM and 1.35 nM for human DHFR and Toxoplasma gondii DHFR. Trimetrexate can also inhibit the growth of various cancer cells. Trimetrexate can be used for researching Pneumocystis carinii pneumonia (PCP) and cancer[1][2][3][4][5].

Product Specifications

CAS Number

[52128-35-5]

Product Name Alternative

CI-898

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Antifolate; Bacterial; Dihydrofolate reductase (DHFR) ; DNA/RNA Synthesis; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/Trimetrexate.html

Purity

99.60

Solubility

DMSO : ≥ 61.5 mg/mL

Smiles

NC1=C(C(C)=C2CNC3=CC(OC)=C(OC)C(OC)=C3)C(C=C2)=NC(N)=N1

Molecular Formula

C19H23N5O3

Molecular Weight

369.42

Precautions

H302, H315, H319, H335

References & Citations

[1]Fulton, B., et al. Trimetrexate. Drugs 49, 563–576 (1995) .|[2]Hopper AT, et al. Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis. J Med Chem. 2019 Feb 14;62 (3) :1562-1576.|[3]Allegra CJ, et al. Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. J Clin Invest. 1987 Feb;79 (2) :478-82.|[4]Dethloff LA, et al. Chronic toxicity of the anticancer agent trimetrexate in rats. Fundam Appl Toxicol. 1992 Jul;19 (1) :6-14.|[5]Grem JL, Voeller DM, Geoffroy F, Horak E, Johnston PG, Allegra CJ. Determinants of trimetrexate lethality in human colon cancer cells. Br J Cancer. 1994 Dec;70 (6) :1075-84.